Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Mabro

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Annales De Pathologie|July 13, 2000
Association of herpes simplex virus encephalitis and paraneoplastic encephalitis - a clinico-pathological studyT Sharshar, I Auriant, A Dorandeu, et al.
British Journal of Cancer|October 17, 2003
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderlyT Aparicio, J Desramé, T Lecomte, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2000
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCORT André, C Louvet, F Maindrault-Goebel, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2001
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)F Maindrault-Goebel, A de Gramont, C Louvet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2006
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR studyT André, C Tournigand, L Mineur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2009
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 studyF-C Bidard, C Tournigand, T André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 6, 2001
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR)F Maindrault-Goebel, A de Gramont, C Louvet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2012
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular studyT André, H Blons, M Mabro, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 22, 2026
Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II studyG M Camilleri, M A Loriot, G Le Teuff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialM Hebbar, B Chibaudel, T André, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Annales De Pathologie|July 13, 2000
Association of herpes simplex virus encephalitis and paraneoplastic encephalitis - a clinico-pathological studyT Sharshar, I Auriant, A Dorandeu, et al.
British Journal of Cancer|October 17, 2003
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderlyT Aparicio, J Desramé, T Lecomte, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2000
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCORT André, C Louvet, F Maindrault-Goebel, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2001
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)F Maindrault-Goebel, A de Gramont, C Louvet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2006
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR studyT André, C Tournigand, L Mineur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2009
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 studyF-C Bidard, C Tournigand, T André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 6, 2001
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR)F Maindrault-Goebel, A de Gramont, C Louvet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2012
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular studyT André, H Blons, M Mabro, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 22, 2026
Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II studyG M Camilleri, M A Loriot, G Le Teuff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialM Hebbar, B Chibaudel, T André, et al.
Pageof 2